Evidence map›Paper›PMID 42292481›Full record

ArticleFrontiers in immunology2026

High-dimensional immune profiling of peripheral blood identifies immune correlates of anti-PD-1/PD-L1 resistance in oncogenic driver mutation-positive NSCLC.

Kyoo Hyun Kim, Mina Han, Geon Woo Park, Min Hee Hong, Gamin Kim, Brian Hyohyoung Lee, Wonrak Son, Jaehyung Kim, Seokhyeong Go, Jeongah Kim and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Kyoo Hyun Kim *Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Mina Han *Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Geon Woo Park *Department of Biomedical Science, Seoul National University Graduate School, Seoul, Republic of Korea.
Min Hee HongDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Gamin KimDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Brian Hyohyoung LeeDepartment of Biomedical Science, Seoul National University Graduate School, Seoul, Republic of Korea.
Wonrak SonDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Jaehyung KimDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Seokhyeong GoDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Jeongah KimDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Geoffrey KellyHuman Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Kai NieHuman Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Seunghee Kim-SchulzeHuman Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Miriam MeradHuman Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Sangwoo KimDepartment of Biomedical Systems Informatics, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.
Chang Gon Kim *Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Hyun Je Kim *Department of Biomedical Science, Seoul National University Graduate School, Seoul, Republic of Korea.
Hye Ryun Kim *Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Non-small cell lung cancer (NSCLC) patients with oncogenic driver mutations such as Methods: A total of 262 NSCLC patients who received PD-1/PD-L1 inhibitor monotherapy between February 2018 and July 2024 were included. Of these, 43 patients were assigned to the discovery cohort, where immune profiling was performed on peripheral blood mononuclear cells using Cytometry by Time-of-Flight (CyTOF) at baseline and cycle 2, day 1 (C2D1). The findings were validated in an independent cohort (n=57) using flow cytometry. Results: Baseline CXCR3 Conclusion: Distinct immune cell profiles highlight elevated baseline CXCR3

Indexed as

B7-H1 AntigenCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmImmune Checkpoint InhibitorsLung NeoplasmsProgrammed Cell Death 1 ReceptorAgedAged, 80 and overBiomarkers, TumorCD8-Positive T-LymphocytesFemaleHumansMaleMiddle AgedMutationB7-H1 AntigenBiomarkers, TumorCD274 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptoranti PD-1/PD-L1 monoclonal antibodycyTOFcytometry by time-of-flightImmune profilingnon-small cell lung cancer (NSCLC)PBMC (peripheral blood mononuclear cells)

Identifiers

PMID42292481
PMCPMC13260270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.